A US claims study described prescription filling after a first ischaemic stroke or TIA in 45,763 adults between July 2020 and December 2024. Fewer than one in five filled a P2Y12 inhibitor within 30 days, and 94.9% of those fills were clopidogrel. Among 5641 continuously enrolled initiators, persistence at 180 days was 50.5% for clopidogrel as compared to 59.6% for ticagrelor.
Why it is interesting: Benchmarks what was actually acquired and continued in routine care, not guideline adherence or comparative effectiveness.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.